Acadian Asset Management LLC Has $101,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Acadian Asset Management LLC lessened its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 40.2% during the second quarter, Holdings Channel reports. The fund owned 17,300 shares of the company’s stock after selling 11,620 shares during the period. Acadian Asset Management LLC’s holdings in Tenaya Therapeutics were worth $101,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in TNYA. UBS Group AG increased its holdings in shares of Tenaya Therapeutics by 22.1% in the first quarter. UBS Group AG now owns 14,729 shares of the company’s stock valued at $42,000 after purchasing an additional 2,669 shares during the last quarter. Bank of America Corp DE grew its stake in Tenaya Therapeutics by 24.2% in the 1st quarter. Bank of America Corp DE now owns 18,305 shares of the company’s stock valued at $216,000 after buying an additional 3,566 shares during the last quarter. California State Teachers Retirement System raised its holdings in Tenaya Therapeutics by 62.2% in the 1st quarter. California State Teachers Retirement System now owns 12,208 shares of the company’s stock valued at $144,000 after acquiring an additional 4,682 shares during the period. Integrated Wealth Concepts LLC lifted its position in Tenaya Therapeutics by 50.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $43,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Tenaya Therapeutics by 70.5% during the fourth quarter. Barclays PLC now owns 15,279 shares of the company’s stock worth $31,000 after acquiring an additional 6,319 shares during the period. Institutional investors and hedge funds own 70.22% of the company’s stock.

Tenaya Therapeutics Price Performance

TNYA stock opened at $1.88 on Tuesday. Tenaya Therapeutics, Inc. has a 52 week low of $1.64 and a 52 week high of $8.09. The business has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $4.42. The company has a market cap of $127.71 million, a PE ratio of -1.00 and a beta of 2.29.

Insider Buying and Selling at Tenaya Therapeutics

In other news, insider Timothy Hoey sold 7,243 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $4.26, for a total transaction of $30,855.18. Following the completion of the sale, the insider now owns 247,396 shares of the company’s stock, valued at approximately $1,053,906.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 33.83% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TNYA shares. Canaccord Genuity Group lowered their target price on Tenaya Therapeutics from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, August 11th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, October 9th. Morgan Stanley boosted their target price on shares of Tenaya Therapeutics from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday, August 10th. Chardan Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Tenaya Therapeutics in a research report on Monday, August 14th. Finally, Lifesci Capital reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Tuesday, August 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.00.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy.